Related Experiment Video
Updated: May 1, 2026

Modeling Encephalopathy of Prematurity Using Prenatal Hypoxia-ischemia with Intra-amniotic Lipopolysaccharide in Rats
Published on: November 20, 2015
Linear programming-based structural lipid optimization of preterm infant formula enhances growth, lipid metabolism,
Yanchen Liu1, Ning Wang1, Guangqing Mu1
1School of Food Science and Technology, Dalian Polytechnic University, Dalian, PR China.
Insights
Optimizing infant formula lipids, especially sn-2 palmitic acid, improves preterm infant growth and metabolic health. This new formula design better mimics human milk lipids for enhanced nutrient absorption and development.
Area of Science:
- Nutritional Science
- Biochemistry
- Pediatrics
Background:
- Preterm birth (<37 weeks) poses significant global health challenges, requiring optimal nutrition for development.
- Human milk (HM) contains unique sn-2 palmitic acid-enriched triacylglycerols (TAGs) crucial for fat absorption and infant development.
- Commercial preterm infant formulas (IFs) often lack these essential lipid structures due to vegetable oil bases.
Purpose of the Study:
- To compare lipidomic profiles of commercial IFs with preterm HM.
- To design an optimized formula (DF) with enhanced sn-2 palmitic acid and HM-like TAG structures.
- To validate the efficacy of the DF in a preterm rat model.
Main Methods:
- Lipidomic profiling of IFs and HM, analyzing fatty acid composition, sn-2 distribution, TAGs, and phospholipids.
- Application of a linear programming model to optimize lipid dimensions for DF design.
- In vivo validation using a preterm rat model to assess growth, organ maturation, and metabolic markers.
Main Results:
- DF demonstrated improved body growth, intestinal villus development, and liver-kidney maturation compared to IFs.
- DF reduced visceral fat, improved lipid distribution, and alleviated hepatic burden.
- DF led to favorable serum profiles: lower triglycerides and LDL-C, higher IGF-1, and preserved liver function.
Conclusions:
- Multidimensional structural lipid optimization, particularly sn-2 palmitic acid enrichment, is key for next-generation preterm formulas.
- The optimized formula (DF) better aligns with HM lipid structures.
- DF shows promise in supporting metabolic health and development in preterm infants.
Abstract:
Preterm birth (<37 weeks) is a major global health challenge, and optimal nutrition is critical for reducing growth restriction, metabolic disorders, and impaired neurodevelopment. Human milk (HM) provides unique lipid structures, notably sn-2 palmitic acid-enriched triacylglycerols (TAGs), which promote efficient fat absorption and physiological development. However, most commercial preterm infant formulas (IFs) lack these structural features due to reliance on vegetable oils. This study compared lipidomic profiles of commercial IFs with preterm HM, focusing on fatty acid composition, sn-2 fatty acid distribution, TAG species, and phospholipids. A linear programming model was applied to coordinately optimize multiple lipid dimensions and design an optimized formula (DF), enriched in OPO and OPL, with higher sn-2 palmitic acid and lower OOO and OPP compared with IFs. Validation in a preterm rat model showed that DF improved body growth, intestinal villus development, and liver-kidney maturation relative to IF. DF also reduced visceral fat accumulation, improved lipid distribution, and alleviated hepatic burden. Serum analysis indicated lower triglycerides and low-density lipoprotein cholesterol (LDL-C), elevated insulin-like growth factor (IGF-1) and growth hormone, and preserved liver function. Digestive product analysis further revealed enhanced retention of polyunsaturated fatty acids at the sn-2 position as 2-monoacylglycerols, promoting absorption while reducing fecal saturated fatty acid-calcium soaps. These findings demonstrate that multidimensional structural lipid optimization, particularly enrichment of sn-2 palmitic acid and HM-like TAGs, represents a promising approach for next-generation preterm formulas to better align with HM and support metabolic health in preterm infants.
Related Concept Videos
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
Designing Growth Media for Bioreactors
Development of the Oral Microbiota

